[an error occurred while processing the directive]
RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Center of early diagnosis of neurodegenerative diseases (TsRD NDZ)

Company


Owners:
Skolkovo UK

Content

Owners

History

2020: Attraction of 30 million rubles of investments

On November 17, 2020 it became known of attraction by "The center of early diagnosis of neurodegenerative diseases" (TsRD NDZ) of investments in the amount of 30 million rubles. The Skolkovo Foundation, says Investment venture fund of the Republic of Tatarstan (IVF RT) invested in the system developer of early diagnosis of Parkinson's disease.

The startup will allocate the received funds for preclinical researches of a test system for determination of quantitative extent of degradation of a nigrostriatny dofaminergichesky system of a brain, the first tranche is listed.

The developer of tests of early diagnosis of Parkinson's disease from Tatarstan attracted 30 million rubles of investments from Skolkovo Foundation

The test system developed by TSRD NDZ allows not only to diagnose Parkinson's disease at a dosimptomny stage, long before emergence of motor symptoms, but also taking into account the dose-dependent nature of effect of pharmacological inhibitor to estimate extent of degradation of a nigrostriatny dofaminergichesky system which is the cornerstone of pathogenesis of this disease.

To the middle of November, 2002 the company completed a phase of preclinical researches of an intranazalny test system for detection of Parkinson's disease at an early stage of a disease and prepares for start of clinical trials in the Russian Federation. A partner of the project is the Institute of biology of development of RAS. Clients of the Company of steel NEOGEN LLC, Kazan state medical university, Himmed Povolzhye LLC, Biotekhnologii LLC, Ekogroup LLC, Aleksionfarm LLC, Kazan scientific center RAS.

According to data which are provided by the press service of IVF RT, the number of patients with Parkinson's disease in the world makes about 0.3% of the general population. The lack of early diagnostics and effective treatment causes the high social and economic importance of Parkinson's disease. Annual direct and indirect costs of one patient in the European Union reach by different estimates according to €3360 - €8160 and €5000 - €6590, in China – $2503 and $722, in the USA – $12,800 and $10,000.[1]

Notes